Scientists have achieved a landmark breakthrough in treating genetic deafness after a single injection into the inner ear successfully restored hearing in patients.
The therapy delivers a healthy version of a critical hearing gene, enabling the inner ear to transmit sound signals to the brain. In early clinical trials, participants—including children and young adults—showed significant improvements in hearing within weeks.
Most were able to perceive speech and environmental sounds clearly, marking a dramatic shift from their previous profound hearing loss. The therapy targets mutations in the OTOF gene, a condition that previously had no cure beyond hearing aids or cochlear implants.
Unlike conventional devices, this approach addresses the underlying genetic cause, offering a long-term solution rather than temporary amplification.
Researchers emphasized the safety and efficacy of the procedure, noting particularly strong results among younger patients. This breakthrough could pave the way for treating a wider range of inherited hearing disorders, giving hope to thousands worldwide.
